Combination of cystic fibrosis medicines to treat patients with rare mutations

View source ↗

Summary

EMA issued a positive opinion to extend the indication of cystic fibrosis modulator medicines so that all patients with modulator-responsive mutations may be el…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Kalydeco (ivacaftor)
• ORKAMBI (lumacaftor and ivacaftor)
• Symdeko (tezacaftor/ivacaftor)
• TRIKAFTA (ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR)

Snippet

Positive opinion for extension of indication brings disease-modifying treatment to all cystic fibrosis patients with modulator responsive mutations